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The Epstein-Barr virus (EBV) immediate-early protein BZLF1 mediates the switch between the latent and
lytic forms of EBV infection and has been previously shown to induce a G1/S block in cell cycle progression in
some cell types. To examine the effect of BZLF1 on cellular gene expression, we performed microarray analysis
on telomerase-immortalized human keratinocytes that were mock infected or infected with a control adeno-
virus vector (AdLacZ) or a vector expressing the EBV BZLF1 protein (AdBZLF1). Cellular genes activated by
BZLF1 expression included E2F-1, cyclin E, Cdc25A, and a number of other genes involved in cell cycle
progression. Immunoblot analysis confirmed that BZLF1 induced expression of E2F-1, cyclin E, Cdc25A, and
stem loop binding protein (a protein known to be primarily expressed during S phase) in telomerase-
immortalized keratinocytes. Similarly, BZLF1 increased expression of E2F-1, cyclin E, and stem loop binding
protein (SLBP) in primary tonsil keratinocytes. In contrast, BZLF1 did not induce E2F-1 expression in normal
human fibroblasts. Cell cycle analysis revealed that while BZLF1 dramatically blocked G1/S progression in
normal human fibroblasts, it did not significantly affect cell cycle progression in primary human tonsil
keratinocytes. Furthermore, in EBV-infected gastric carcinoma cells, the BZLF1-positive cells had an in-
creased number of cells in S phase compared to the BZLF1-negative cells. Thus, in certain cell types (but not
others), BZLF1 enhances expression of cellular proteins associated with cell cycle progression, which suggests
that an S-phase-like environment may be advantageous for efficient lytic EBV replication in some cell types.
Epstein-Barr virus (EBV) is a human gammaherpesvirus
and is known to be the causative agent of infectious mononu-
cleosis (37, 57). EBV infection has also been associated with a
growing number of malignancies (48, 57). EBV can infect cells
in either the latent or lytic form. EBV infection in B cells is
predominantly latent, and only a small subset of the viral genes
is expressed (57). Expression of one of the EBV immediate-
early (IE) proteins, BZLF1 or BRLF1, induces the switch from
latent to lytic infection, allowing the virus to form new particles
and be transferred to new host cells (15, 16, 55, 60, 73, 81).
Although the role of epithelial cell infection in normal EBV
pathogenesis remains controversial (24, 65, 66), it is clear that
EBV infection is important in the development of certain ep-
ithelial tumors (in particular, nasopharyngeal carcinoma) (48).
In addition, in immunocompromised patients, EBV causes le-
sions involving epithelial cells along the lateral border of the
tongue known as oral hairy leukoplakia (OHL). OHL is pri-
marily, if not exclusively, due to the lytic form of EBV infection
(76).
BZLF1 is a transcriptional activator which binds to AP-1-
like sequences (17, 25, 26, 30, 36, 39, 74), and binding sites for
BZLF1 are present in most early EBV promoters, as well as
the BRLF1 IE promoter (2, 13, 22, 25, 49, 54). BZLF1 initially
activates expression of BRLF1. BZLF1 and BRLF1 together
are then sufficient to activate expression of the lytic viral rep-
lication proteins, followed by the subsequent replication and
packaging of the virus (37).
In addition to its effects on IE and early EBV gene tran-
scription, BZLF1 profoundly affects the host cell environment.
For example, our research group has shown that BZLFl acti-
vates the host cell stress map kinase signaling pathway (1),
inhibits host cell gamma interferon signaling (45), and interacts
with the tumor suppressor protein p53 (82). These effects of
BZLF1 on the host cell environment presumably serve to en-
hance the efficiency of lytic virus replication.
Many viruses have been shown to manipulate the host cell
cycle progression in order to create the optimal conditions for
viral replication. Small DNA tumor viruses, which use the host
cell DNA polymerase and are completely dependent upon the
host cell for nucleotide substrates, drive cells into S phase
through the expression of viral proteins which inhibit the func-
tions of p53 and pRb (70). However, the effects of the larger
herpesviruses on cell cycle progression are more complex.
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While the lytic form of herpes simplex virus (HSV) infection
induces a G1 block (21, 67), lytic human cytomegalovirus
(HCMV) infection has been reported to either inhibit or en-
hance cell cycle progression (19, 32, 43, 61, 64). Given the
larger genome of herpesviruses, which encodes a DNA poly-
merase as well as a number of DNA-modifying enzymes, the
replication of these viruses is much less dependent than the
smaller DNA viruses on the host cell. Instead, competition
with the host cell for limiting nucleotide pools may be of
greater concern for herpesviruses; thus, it could be advanta-
geous for these viruses to prevent host cell DNA replication.
In the case of EBV, viral proteins expressed during type III
latency induce cell cycle progression in B cells (9, 50, 51, 68),
contributing to the transforming capacity of EBV. However,
the effect of lytic EBV infection on cell cycle progression has
not been well studied, in part because there is no cell culture
system at present that supports efficient primary lytic EBV
infection. Using Burkitt’s lymphoma lines treated with various
inducing agents (which convert a portion of the cells from the
latent to lytic form of infection), one group reported that
BZLF1-positive cells are primarily in the G0/G1 or G2/M
phases of the cell cycle (59), whereas another group found
BZLF1-positive cells distributed throughout the cell cycle (31).
A potentially confounding variable in these previous studies is
that the agents used to induce lytic EBV infection (anti-immu-
noglobulin M [anti-IgM], phorbol esters, and transforming
growth factor ) are quite toxic and produce cell cycle effects
and/or apoptosis even in the absence of EBV. In addition,
previous studies examining the effects of lytic EBV infection
were performed in tumor cell lines, which are likely deficient in
healthy cell cycle control mechanisms.
The cell cycle effects of lytic HSV and HCMV infection are
primarily attributable to expression of the viral IE proteins (6,
10, 29, 35, 42, 46, 79). Assuming that this is also the case with
EBV, we have been examining the effects of BRLF1 and
BZLF1 expression on cell cycle progression in various cell
types. We previously reported that BRLF1 induces S-phase
progression in normal human fibroblasts (71), which is likely
due to its abilities to bind pRb, and increases the level of
cellular E2F-1 (71, 80). In contrast, expression of the IE pro-
tein BZLF1 has been reported by another group to cause a
G0/G1 arrest in several epithelial cell tumor lines, with an
associated increase in p21, p27, and hypophosphorylated pRb
(11, 12, 58). To date, however, the cell cycle effect of BZLF1
has not been examined in primary cell lines.
In this report, we demonstrate that BZLF1 activates expres-
sion of a number of cellular proteins associated with G1/S
progression in primary human keratinocytes (including E2F-1,
cyclin E, and SLBP), as well as in telomerase-immortalized
human keratinocytes. In contrast, BZLF1 does not activate
E2F-1 expression in normal human fibroblasts. While BZLF1
expression in primary human fibroblasts results in a profound
G0/G1 block, it does not significantly inhibit cell cycle progres-
sion in telomerase-immortalized, or primary, keratinocytes.
Furthermore, we find that the BZLF1-positive population in
gastric carcinoma cells infected with EBV contains an in-
creased number of cells in S phase. Our results indicate that
BZLF1 has cell type-dependent effects on cell cycle progres-
sion. The ability of lytic EBV infection to induce an S-phase-
like environment in certain epithelial cell types correlates well
with the hyperproliferative nature of OHL.
MATERIALS AND METHODS
Cell culture. Telomerase-immortalized human keratinocytes (clone 22) were
originally derived from human neonatal foreskin as previously described (23).
Telomerase-immortalized human keratinocytes were maintained in Keratino-
cyte-SFM medium (Gibco-BRL) with epidermal growth factor and bovine pitu-
itary extract added. The AGS-EBV cell line (a generous gift from Lindsey
Hutt-Fletcher) was obtained by G418 selection of AGS cells (a gastric carcinoma
cell line) that were infected with a recombinant Akata virus in which a neomycin
resistance cassette had been inserted into the nonessential BDLF3 open reading
frame. Both the control AGS cell line and the AGS-EBV cell line were main-
tained in Ham’s F12 medium, supplemented with 10% fetal bovine serum (FBS).
Normal human fibroblasts were derived from neonatal foreskin as previously
described (34). Normal human fibroblasts were maintained in Eagle’s minimal
essential medium, supplemented with 10% FBS and nonessential amino acids.
All media contained penicillin (100 U/ml) and streptomycin (100 g/ml). The
cells were maintained at 37°C in a humidified atmosphere containing 10% CO2.
Isolation of primary human oropharyngeal epithelial cells. Human oropha-
ryngeal mucosa from surgical specimens (tonsillectomy and uvulectomy) was
used as a source of primary keratinocytes. Surgical specimens were collected in
Dulbecco’s modified Eagle medium (DMEM) containing 10% FBS and supple-
mented with penicillin (50 g/ml) and streptomycin (50 g/ml) at 4°C. Primary
cultures were established by a modified version of the method developed for the
cultivation of epidermal keratinocytes (56). By using surgical instruments, 2 to 3
cm2 of mucosa from the anterior tonsillar pillar or uvula was dissected away from
underlying tissue. Mucosa was then disinfected by immersion in a solution of 1%
povidone iodine for 5 min followed by serial rinses in phosphate-buffered saline
(PBS). Mucosa was incubated in 10 ml of 0.25% trypsin (Gibco-BRL) at 4°C for
12 h with agitation. The contents of the digest were added to keratinocyte
serum-free medium (KSFM; Gibco-BRL) with 10% FBS, and larger tissue frag-
ments remaining were removed, cut cross-wise with a scalpel, and resuspended.
After vigorous pipetting, the sample was passed through a 100-m-pore-size
nylon cell strainer (Falcon 2360), centrifuged, and resuspended in KSFM with
10% FBS. Cells were plated onto collagen-coated plates (0.1 mg of collagen IV
per ml in PBS) with a feeder layer of mitomycin C-treated NIH 3T3 fibroblasts
(72) and grown at 37°C in KSFM containing 10% FBS supplemented with
epidermal growth factor (5 ng/ml), bovine pituitary extract (50 g/ml), penicillin
(100 U/ml), streptomycin (100 g/ml), ceftazidime (100 g/ml), tobramycin (40
g/ml), and amphotericin (1 g/ml). The medium was changed every 2 days, and
when cells were nearly confluent, KSFM containing 10% FBS was replaced by
KSFM with no serum added. When there were sufficient cells for experimenta-
tion, detachment was accomplished using 0.05% trypsin-EDTA (Gibco-BRL)
followed by plating onto collagen-coated plastic tissue culture plates in the
absence of a feeder layer.
Adenoviral vectors and infections. An E1/E3-deficient adenovirus 5 vector
expressing the EBV IE protein BZLF1 cDNA (under the control of a HCMV
promoter) was made using the recombinant Cre-lox-mediated recombination
system as previously described (AdBZLF1) (77). The control adenovirus vector
(AdLacZ) is identical to AdBZLF1, except that it contains the bacterial -ga-
lactosidase gene in place of the BZLF1 cDNA. All adenovirus preparations used
in this manuscript were confirmed to be free of any detectable wild-type virus and
did not produce any detectable E1A after infection of cells.
Adenovirus infections were performed as follows. Telomerase-immortalized
human keratinocytes were plated at a density of 2  106 cells per 150-mm-
diameter plate and infected at an multiplicity of infection (MOI) of 20. The
MOIs of various preparations was determined by plaque formation in 293 cells.
Primary tonsil keratinocytes were plated at a density of 105 cells per 60-mm-
diameter plate and infected at an MOI of 30. AGS and AGS-EBV cells were
plated at a cell density of 2  106 per 150-mm-diameter plate and infected at an
MOI of 5. Normal human fibroblasts were plated at a cell density of 107 per
150-mm-diameter plates, serum starved for 3 days, infected at an MOI of 250 in
the absence of serum, 24 h later split 1:5, and replated in the presence of 10%
serum. The adenovirus MOI required for each cell type was determined by using
an adenovirus expressing the green fluorescence protein or by performing im-
munofluorescence on AdBZLF1-infected cells and determining the minimal
dose required to infect the majority of cells.
Affymetrix GeneChip analysis. Telomerase-immortalized human keratinocytes
were plated at a cell density of 2  107 per 150-mm-diameter dish and then either
mock infected or infected with adenovirus expressing LacZ or BZLF1 at an MOI
of 17. The cells were harvested 48 h later, and total RNA was obtained using the
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RNAeasy kit (Qiagen). From each condition, cDNA was then synthesized using
a T7-(dT)24 primer (cDNA kit from Life Technologies). Biotinylated cRNA was
then generated from the cDNA reaction mixture using the BioArray high-yield
RNA transcript kit. The cRNA was then fragmented in fragmentation buffer (5
fragmentation buffer consists of 200 mM Tris-acetate [pH 8.1], 500 mM potas-
sium acetate, and 150 mM magnesium acetate) at 94°C for 35 min before the chip
hybridization. Fifteen micrograms of fragmented cRNA was then added to a
hybridization cocktail. The hybridization cocktail contains the following ingredi-
ents: 0.05 g of fragmented cRNA per l; 50 pM control oligonucleotide B2;
BioB, BioC, BioD, and cre hybridization controls; 0.1 mg of herring sperm DNA
per ml; 0.5 mg of acetylated bovine serum albumin (BSA) per ml; 100 mM
morpholineethanesulfonic acid (MES); 1 M Na; 20 mM EDTA; 0.01% Tween
20; and the GeneChip HuGeneFL Array, which provides gene expression data
for approximately 5,000 full-length human sequences. Arrays were hybridized for
16 h in the GeneChip Fluidics Station 400 and were washed and scanned with the
Hewlett-Packard GeneArray Scanner. During the washing, the cRNA probe was
labeled with R-phycoerythrin streptavidin. Affymetrix GeneChip Microarray
Suite 4.0 software was used for washing, scanning, and basic analysis. Sample
quality was assessed by examination of 3 to 5 intensity ratios of certain genes.
Cell cycle analysis. Cells were infected as described above. Forty-eight hours
after infection, cells were incubated with 10 M bromodeoxyuridine (BrdU) for
60 min at 37°C. Cells were then trypsinized, washed once in 1 PBS, fixed in 1.5
ml of cold 1 PBS plus 3.5 ml of ice-cold 95% ethanol, and incubated at 20°C
overnight. After fixation, cells were pelleted, resuspended in 3 ml of 0.8% pepsin
in 0.1 N HCl, and incubated for 20 min at 37°C. Lysates were centrifuged, nuclear
pellets were suspended in 1.5 ml of 2N HCl, and the suspensions were incubated
at 37°C for 20 min. Subsequently 3 ml of 0.1 M sodium borate was added, and the
lysates were repelleted. The nuclear pellets were washed in indirect immunoflu-
orescence assay buffer (IFA) (10 mM HEPES [pH 7.4], 150 mM NaCl, 4% FBS,
0.1% sodium azide) containing 0.5% Tween 20. They were then stained with
anti-BrdU antibody (1:50; Becton Dickinson) in IFA at room temperature (RT)
for 1 h, washed with IFA containing Tween 20, counterstained with fluorescein
isothiocyanate-conjugated goat anti-mouse IgG (whole molecule) (diluted 1:100)
(Sigma) in IFA at RT for 1 h, and washed with IFA containing Tween 20.
Nuclear pellets were suspended in IFA containing 500 g of RNase A and 50 g
of propidium iodide per ml and incubated at 37°C for 15 min. Fluorescence was
measured with a fluorescence-activated cell sorter (FACS; Becton Dickinson).
To compare the number of cells in S phase in BZLF1-positive versus BZLF1-
negative AGS-EBV cells, trypsinized AGS-EBV cells were washed once in 1
PBS, fixed in 1.5 ml of cold 1 PBS plus 3.5 ml of ice-cold 95% ethanol, and
incubated at 20°C overnight. Cells were then washed with 1 PBS–0.5% bovine
serum albumin (BSA), stained with anti-BZLF1 antibody (diluted 1:100) (Ar-
gene) in PBS–0.5% BSA for 60 min, washed with 1 PBS–0.5% BSA, and
counterstained with fluorescein isothiocyanate-conjugated goat anti-mouse IgG
(whole molecule) (diluted 1:100) in 1 PBS–0.5% BSA for 60 min. Cells were
then washed, resuspended in 1 PBS containing 500 g of RNase A per ml and
50 g of propidium iodide per ml, and incubated at 37°C for 15 min. Fluorescence
was measured with a FACS. Cells which were BZLF1 positive (approximately
4% of the total AGS-EBV population) were identified using the BZLF1-specific
antibody and by comparison between the AGS-EBV-positive and AGS-EBV-
negative cell lines. The percentage of BZLF1-positive versus BZLF1-negative
AGS-EBV cells in S phase was then determined by comparing the propidium
iodine staining of each population, using Mod-Fit LT analysis. At least 3,000
BZLF1-positive AGS-EBV cells in each of three different experiments were
counted to determine the cell cycle distribution of BZLF1-positive cells.
Immunoblotting. Cell extracts were prepared as previously described (1).
Proteins (50 to 100 g) were separated by polyacrylamide gel electrophoresis and
blotted onto a nitrocellulose membrane. The membranes were then blocked in
blocking buffer (1 PBS, 0.1% Tween 20, 5% milk) at RT for 60 min and then
incubated at RT for 60 min with primary antibody in blocking buffer. The
primary antibodies included anti-E2F-1 rabbit polyclonal antibody (diluted
1:500; C20 [Santa Cruz]), anti-cyclin E mouse monoclonal antibody (1:500;
BF683 [Santa Cruz]), Cdc25A mouse monoclonal antibody (1:500; F-6 [Santa
Cruz]), SLBP rabbit polyclonal antibody (1:2,000; a generous gift of William
Marzluff, University of North Carolina at Chapel Hill), and anti-BZLF1 mouse
monoclonal antibody (1:200; AZ-69 [Argene]). The membranes were washed in
wash buffer (1 PBS, 0.1% Tween 20) and incubated with horseradish peroxi-
dase-conjugated secondary antibody (1:10,000) (Promega) at RT for 60 min. The
membranes were washed in wash buffer, and proteins were detected by using an
enhanced chemiluminescence (ECL) kit (Amersham).
Apoptosis assay. Cellular apoptosis was quantitated as suggested by the man-
ufacturer using the ApoAlert Annexin V kit (Clontech), which measures phos-
phatidylserine on the cell membrane.
RESULTS
Microarray analysis of AdBZLF1-infected telomerase-im-
mortalized human keratinocytes. To examine the effect of
BZLF1 on host cell gene expression, telomerase-immortalized
keratinocytes were either mock infected or infected with
adenovirus vectors expressing LacZ (AdLacZ) or BZLF1
(AdBZLF1). At 2 days postinfection, cells were harvested and
cellular RNA was analyzed using the Affymetrix GeneChip.
Interestingly, infection of keratinocytes with the BZLF1 ade-
novirus vector induced expression of a number of cellular
genes, including E2F-1, DP-1, cyclin A, Cdc25A, and cyclin E,
which are important for entry into S phase (3, 33, 63), as well
as genes (including thymidine kinase and thymidylate kinase)
that are expressed preferentially in S phase (41) (Table 1).
Although BZLF1 was previously shown to induce a G0/G1
block in HeLa cells (11, 12), the results of the microarray
experiment in telomerase-immortalized human keratinocyte
cells suggested that BZLF1 is unlikely to induce a G0/G1 cell
cycle block in this cell type and instead may be activating cell
cycle progression.
BZLF1 increases the levels of E2F-1, cyclin E, SLBP, and
Cdc25A in keratinocytes. To confirm the results of the mi-
croarray experiment, we performed immunoblot analyses to
examine the effects of BZLF1 on the levels of E2F-1, cyclin A,
Cdc25A, and SLBP in telomerase-immortalized human kera-
tinocytes, primary tonsil keratinocytes, and the AGS gastric
carcinoma line. The E2F-1 protein is known to be both essen-
tial and sufficient for S-phase entry (38, 47) and activates ex-
pression of both cyclin E and Cdc25A (18, 69, 75). Cyclin E is
essential for progression from early to late G1 (62), whereas
the Cdc25A tyrosine phosphatase is essential for activation of
cyclin-dependent kinases in G1 (14, 27). SLBP, which is im-
portant for histone mRNA processing, is primarily expressed
during cellular S phase (78).
As shown in Fig. 1, BZLF1 increased the level of cellular
E2F-1 in telomerase-immortalized human keratinocytes, pri-
mary tonsil keratinocytes, and AGS cells, whereas it had no
effect on the level of -actin. In contrast, BZLF1 did not
increase the level of E2F-1 in normal human fibroblasts, even
though it was expressed at a similar level in these cells. Con-
sistent with its ability to induce E2F-1 in telomerase-immor-
talized keratinocytes, BZLF1 also enhanced expression of cy-
clin E, CDC25, and SLBP in these cells (Fig. 2A). Similarly,
BZLF1 enhanced expression of the SLBP in primary keratin-
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a RNA from telomerase-immortalized human keratinocytes, mock infected or
infected with AdLacZ or AdBZLF1, was analyzed by microarray analysis using
the Affymetrix GeneChip HuGeneFL Array.
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ocytes and AGS cells (Fig. 2B), but not in normal human
fibroblasts (Fig. 2A). Infection of AGS cells and telomerase-
immortalized keratinocytes with the BZLF1 adenovirus vector
at the MOI used in these experiments resulted in a level of
cellular BZLF1 expression similar to that of the BZLF1-posi-
tive population of AGS cells infected with the intact virus (Fig.
1C). These results suggest that BZLF1 induces E2F-1 expres-
sion, and consequently activation of E2F-1-regulated genes, in
a cell-specific manner.
BZLF1 regulates the host cell cycle in a cell type-dependent
manner. Telomerase-immortalized human keratinocytes, pri-
mary keratinocytes, and normal human fibroblasts were mock
infected or infected with the AdLacZ or AdBZLF1 vectors,
and the effect on cell cycle progression was analyzed by FACS
analysis. Infection of serum-starved normal human fibroblasts
with the AdBZLF1 vector completely inhibited the ability of
these cells to enter S phase following serum stimulation (Fig.
3). AdBZLF1 infection also dramatically reduced the number
of healthy human fibroblast cells in S phase in asynchronously
growing cultures (data not shown). In contrast, BZLF1 expres-
sion produced only a mild G1/S block in the telomerase-im-
mortalized human keratinocytes and AGS cells and did not
significantly affect cell cycle progression in primary keratino-
cytes. Thus, similar to its effects on E2F-1 activation, BZLF1
produces very different effects on host cell cycle progression in
telomerase-immortalized and primary human keratinocytes
versus normal human fibroblasts.
The BZLF1 effect on p53 is also dependent on the cell type.
Many viruses regulate cell cycle progression through their ef-
fects on the p53 tumor suppressor protein. p53 transcription-
ally activates p21, which inhibits the cyclin-dependent kinases.
We have previously shown that BZLF1 interacts with and sta-
bilizes the p53 protein (82). There is some evidence that sta-
bilization of p53 may contribute to the ability of BZLF1 to induce
cell cycle block in some cell types (12), although we have found
that BZLF1 inhibits the transcriptional function of p53 (82).
To determine if the effect of BZLF1 expression on p53 is
also dependent on the cell type, normal human fibroblasts,
telomerase-immortalized or primary human keratinocytes, and
AGS cells were mock infected or infected with the AdLacZ or
AdBZLF1 vector, and immunoblot analysis for p53 was per-
formed on cell extracts 2 days later. Each of these lines has
wild-type p53. As shown in Fig. 4, BZLF1 expression increased
the level of cellular p53 in normal human fibroblasts, whereas
it had little effect on the level of p53 in keratinocytes and AGS
cells. Thus, the ability of BZLF1 to stabilize p53 also appears
to be cell type dependent.
BZLF1 does not induce significant apoptosis in telomerase-
immortalized human keratinocytes. Overexpression of E2F-1
has been shown to induce apoptosis in many cell types (20, 52).
We therefore investigated whether BZLF1 enhances apoptosis
in keratinocytes. Annexin V binding to mock-infected or Ad-
LacZ- and AdBZLF1-infected telomerase-immortalized hu-
man keratinocytes was quantitated by FACS analysis, as shown
in Fig. 5. Annexin V binding was not significantly enhanced in
the BZLF1-positive cells versus the AdLacZ-infected cells.
Similarly, we have previously reported that BZLF1 does not
induce apoptosis in normal human fibroblasts (77). Thus,
BZLF1 induction of E2F-1 expression is apparently not ac-
companied by significant apoptosis, possibly due to the previ-
ously noted ability of BZLF1 to inhibit p53 function.
The BZLF1-positive subset of AGS-EBV cells has an in-
creased number of cells in S phase. The above results suggest
that BZLF1 expression in keratinocytes activates expression of
some cellular proteins normally associated with cell cycle pro-
gression but is not sufficient by itself to induce full S-phase
progression. We previously reported that the other EBV IE
protein, BRLF1, activates S-phase progression in normal hu-
man fibroblasts. Therefore, BZLF1 and BRLF1 together might
be sufficient to induce S-phase progression during lytic EBV
infection in certain cell types.
To determine whether lytic EBV infection is associated with
S-phase progression in the context of normal EBV infection,
we compared the cell cycle distributions of the BZLF1-positive
and BZLF1-negative subsets of AGS cells superinfected with
EBV. Approximately 4% of AGS-EBV cells express BZLF1
constitutively (Fig. 2C), allowing us to avoid the use of toxic
chemical agents that are required for the induction of BZLF1
FIG. 1. BZLF1 induces E2F-1 in a cell type-dependent manner.
(A) Telomerase-immortalized human keratinocytes and normal hu-
man fibroblasts were infected with AdLacZ or AdBZLF1. At 48 h
postinfection, the levels of E2F-1, BZLF1, and -actin were quanti-
tated by immunoblot analysis. (B) AGS gastric carcinoma cells and
primary tonsil keratinocytes were infected as in panel A, and the level
of E2F-1 was determined by immunoblot analysis. NS, nonspecific
cross-reacting band. (C) FACS analysis was performed to compare the
level of BZLF1 expression in Ad-BZLF1-infected AGS cells or telom-
erase-immortalized keratinocytes to that in the constitutively BZLF1-
positive population of EBV-AGS cells. Neg., negative; Pos., positive.
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expression in most other EBV-positive cell lines. The percent-
age of BZLF1-positive and BZLF1-negative cells in each stage
of the cell cycle (from three separate experiments) is shown in
Fig. 6; the cell cycle distribution of at least 3,000 BZLF1-
positive AGS cells was determined in each experiment. The
BZLF1-positive cells had significantly more cells in S phase
than the BZLF1-negative cells. Similar results were obtained
in the presence of acyclovir, which inhibits the lytic form of
EBV replication and prevents expression of viral late genes
(data not shown) (37, 57). These results suggest that the two
EBV IE proteins together (BZLF1 and BRLF1) induce S-
phase progression within the context of normal lytic EBV in-
fection in AGS cells.
DISCUSSION
Many viruses manipulate the host cell environment in order
to optimize the conditions for viral replication. HSV and
HCMV have both been shown to affect cell cycle regulation
during the lytic form of infection, suggesting that lytic EBV
infection might likewise regulate the host cell cycle progres-
sion. In this study, we have investigated the cell cycle effects of
the EBV IE protein BZLF1 in primary (or telomerase-immor-
talized) keratinocytes versus normal human fibroblasts. Al-
though it has previously been reported that BZLF1 inhibits cell
cycle progression in a variety of tumor cell lines (11, 12, 59),
the effect of BZLF1 on cell cycle progression in primary cells
has not been previously studied. Somewhat surprisingly, we
show here that the cell cycle effects of BZLF1 are dramatically
cell type dependent. Thus, while BZLF1 inhibits cell cycle
progression in normal human fibroblasts (a cell type not nor-
mally infected by EBV), it does not significantly inhibit S-phase
entry in primary and telomerase-immortalized keratinocytes (a
natural target cell for the lytic form of EBV infection) and
instead enhances expression of several cellular proteins nor-
mally associated with cell cycle progression. The cell cycle
effects of BZLF1 in primary keratinocytes correlate with the
FIG. 1—Continued.
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known ability of lytic EBV infection to induce a hyperprolif-
erative epithelial lesion, OHL.
Our results show that the ability of BZLF1 to induce expres-
sion of the critical cell cycle regulator E2F-1 is cell type de-
pendent. E2F-1 overexpression by itself is often sufficient to
activate entry into S phase, although there is usually concom-
itant apoptosis (20, 38, 47, 52). E2F-1 transcriptionally acti-
vates many genes associated with DNA synthesis and S-phase
progression, in particular cyclins E and A and Cdc25A (18, 69,
75). A number of stimuli, including DNA damage and activa-
tion of the ATM kinase, have recently been shown to induce
cellular E2F-1 expression by increasing E2F-1 protein stabil-
ity (40). However, given the results of the microarray assay
in telomerase-immortalized human keratinocytes (in which
E2F-1 RNA level was increased 16-fold in AdBZLF1-infected
cells), the effect of BZLF1 on E2F-1 is likely to be mediated at
least partially at the RNA level, rather than the protein level.
The cell type-dependent nature of the BZLF1 cell cycle
effect correlates with its ability to enhance the level of E2F-1 in
a cell type-specific manner. At this point, we are uncertain why
BZLF1 activates E2F-1 in some cell types, but not others.
Assuming that BZLF1 transcriptionally activates the E2F-1
promoter, BZLF1 may not be able to activate the E2F-1 pro-
moter in certain cell types due to promoter binding of nega-
tively regulating cellular factors, methylation, or inaccessible
chromatin. Alternatively, we have previously shown that the
ability of BZLF1 to transcriptionally activate certain early
EBV promoters is also cell type dependent (30). Thus, cell
type-dependent modification of the BZLF1 protein may alter
its ability to activate or bind to some promoters. Consistent
with this, we previously showed that mutation of BZLF1 resi-
due 186, which is known to be phosphorylated in vivo (4),
inhibits its ability to bind to the viral BRLF1 IE promoter but
not the early BMRF1 promoter (2).
Our findings that BZLF1 expression by itself is apparently
not sufficient to activate full S-phase progression in keratino-
cytes or AGS cells whereas the lytically infected population of
EBV-positive AGS cells has an increased number of cells in S
phase suggest that BZLF1 may cooperate with other lytic EBV
proteins to activate S-phase progression in certain cell types.
We previously reported that the other EBV IE protein, BRLF1,
also induces E2F-1 expression in a variety of cell types, including
healthy human fibroblasts and HeLa cells, although the exact
mechanism for this effect has not been defined (71). Interest-
ingly, microarray analysis of telomerase-immortalized human
keratinocytes infected with a BRLF1 adenovirus vector also
showed increased expression of many cellular genes associated
with cell cycle progression but did not indicate enhanced ex-
pression of the E2F-1 gene itself (A. Mauser and S. Kenney,
unpublished data). In contrast, immunoblot analysis of
AdBRLF1-infected telomerase-immortalized human keratino-
cytes confirmed that BRLF1 expression does increase the level
of E2F-1 protein (Mauser and Kenney, unpublished). Thus,
BZLF1 and BRLF1 activate E2F-1 through two different
mechanisms in keratinocytes: BZLF1 increases the level of
E2F-1 RNA, whereas BRLF1 increases E2F-1 through a post-
transcriptional mechanism. The combined expression of BZLF1
and BRLF1 may activate S-phase progression in certain cell
types such as AGS cells. Alternatively, in other cell types, it
remains possible that BZLF1- and BRLF1-induced activation
of E2F-1 results in the expression of host cell genes normally
restricted to the late G1- or S-phase portions of the cell cycle but
does not actually result in concomitant cell cycle progression.
In some respects, our results here are reminiscent of previ-
ous studies examining the cell cycle effects of the HCMV IE
proteins. HCMV infection has been shown to upregulate the
expression of a variety of cellular proteins normally involved in
cell cycle progression, including c-myc, c-fos, c-jun, and cyclin
E (5, 32), (44) and induces hyperphosphorylation of Rb (32).
HCMV replication has been shown to require cyclin E/cdk2
(7), and thus, it would clearly be advantageous for the virus to
induce cell cycle progression in quiescent host cells that nor-
mally do not have activated cdk2. Whether HCMV-infected
cells actually enter S phase, versus accumulate in late G1, is
somewhat controversial. One group reported that HCMV in-
fection of irreversibly arrested cells induces cell cycle progres-
sion into early S phase (64), whereas other groups have shown
that HCMV infection blocks cells in late G1 (8, 32, 43, 61). As
FIG. 2. BZLF1 increases the expression of E2F-1-responsive genes
in some cell types. (A) Telomerase-immortalized keratinocytes or nor-
mal human fibroblasts were mock infected or infected with the Ad-
LacZ or AdBZLF1 vector. Immunoblot analysis was performed 2 days
later to quantitate expression of cyclin E, SLBP, or Cdc25A, as indi-
cated. (B) AGS and primary tonsil keratinocytes were infected with the
AdLacZ or AdBZLF1 vector, and immunoblot analysis was performed
2 days later to quantitate expression of cyclin E and SLBP as indicated.
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is the case with EBV, both of the HCMV IE proteins, the72-
kDa IE1 protein and the 86-kDa IE2 protein, appear to con-
tribute to the cell cycle effects of HCMV. IE1 binds and inac-
tivates p107 (53), while IE2 binds and inactivates pRb (28),
thus increasing E2F transcriptional activity. IE2 also upregu-
lates cyclin E through a direct mechanism (6). Both IE proteins
have also been shown to induce the cell cycle in serum-starved
cells (10, 46, 79).
FIG. 3. BZLF1 has cell type-dependent effects on cell cycle progression. Normal human fibroblasts, primary keratinocytes, telomerase-
immortalized keratinocytes, or AGS cells were infected with the AdLacZ or AdBZLF1 vector. Two days later, the cells were labeled for 1 h with
10 M BrdU, harvested, fixed, and stained with propidium iodide. BrdU incorporation was quantitated by FACS analysis using a BrdU monoclonal
antibody and a fluorescein isothiocyanate-labeled secondary antibody.
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In contrast, HSV infection has been associated only with the
induction of a G1 cell cycle block (21, 67), and the expression
of the ICP0 HSV IE protein by itself causes cell cycle arrest in
both the G1 and G2/M components of the cell cycle (29, 42).
Whether these differences in cell cycle effects reflect a funda-
mental difference in HCMV and EBV pathogenesis on the one
hand and HSV pathogenesis on the other hand remains to be
determined. In support of this, both EBV and HCMV infec-
tion are associated with hyperproliferative lesion in patients
(OHL and coronary artery restenosis), while this is not the case
for HSV. However, as shown by the data presented here,
misleading results may be obtained by studying the cell cycle
effects of herpesviruses in vitro using cell lines which are not
the normal target cells for viral infection in vivo.
Clearly, it will be important to determine the effects of the
EBV IE proteins on cell cycle control in primary B cells. All
previous studies examining BZLF1 cell cycle effects in B cells
have been done using Burkitt’s lymphoma lines (in which c-
myc expression is obviously dysregulated), as well as toxic
agents which are required to induce the lytic form of infection
(31, 59). Thus, the results of such studies may not be applicable
to the effect of BZLF1 in primary resting B cells, the normal
target for EBV infection in humans. Unfortunately, as primary
B cells are not readily transfectable with DNA plasmids or
infectible with adenovirus vectors, the answer to this question
may not be forthcoming in the near future. If lytic EBV infec-
tion activates cell cycle progression during primary infection of
B cells, this effect could contribute to hyperproliferation of B
cells during primary mononucleosis.
FIG. 4. BZLF1 affects p53 level in a cell type-dependent manner. Primary or telomerase-immortalized keratinocytes and AGS cells or normal
human fibroblasts were mock infected or infected with AdLacZ or AdBZLF1. Immunoblot analysis was performed 48 h after infection to
quantitate the level of cellular p53.
FIG. 5. BZLF1 induction of E2F-1 is not associated with apoptosis.
Telomerase-immortalized human keratinocytes were mock infected or
infected with AdLacZ or AdBZLF1. At 48 h postinfection, the binding of
Annexin V-fluorescein isothiocyanate was quantitated by FACS analysis.
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